2.4.0.84141 - Disclosure - Acquisitions, License and Research Agreements (Details 2)truefalseIn Millions, unless otherwise specifiedfalse1false USDfalsefalse$D2013Q3_M07_CostmethodInvestmentsMember_VariableInterestEntityNotPrimaryBeneficiaryMemberhttp://www.sec.gov/CIK0000946840duration2013-07-01T00:00:002013-07-31T00:00:00PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$D2011Q4_M12_VariableInterestEntityNotPrimaryBeneficiaryMember_CostmethodInvestmentsMemberhttp://www.sec.gov/CIK0000946840duration2011-12-01T00:00:002011-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$D2013Q2_CostmethodInvestmentsMember_VariableInterestEntityNotPrimaryBeneficiaryMemberhttp://www.sec.gov/CIK0000946840duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$D2012Q3_VariableInterestEntityNotPrimaryBeneficiaryMember_CostmethodInvestmentsMemberhttp://www.sec.gov/CIK0000946840duration2012-07-01T00:00:002012-09-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$D2012Q2_CostmethodInvestmentsMember_VariableInterestEntityNotPrimaryBeneficiaryMemberhttp://www.sec.gov/CIK0000946840duration2012-04-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDfalsefalse$D2013Q2YTD_VariableInterestEntityNotPrimaryBeneficiaryMember_CostmethodInvestmentsMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDfalsefalse$D2012Q2YTD_VariableInterestEntityNotPrimaryBeneficiaryMember_CostmethodInvestmentsMemberhttp://www.sec.gov/CIK0000946840duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0License and research agreements disclosures2false 4vphm_BusinessAcquisitionOptionalPurchaseAgreementOutstandingStockPurchasePricevphm_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse6990000069.9USD$falsetruefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryPer terms of an exclusive option for the acquisition of a business, the agreed upon purchase price of the outstanding stock if the option to purchase is exercised by the reporting entity.No definition available.false2Agreed upon purchase price of the outstanding stock per optional purchase agreement3false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse2false USDtruefalse$I2013Q2_VariableInterestEntityNotPrimaryBeneficiaryMember_MaximumMemberhttp://www.sec.gov/CIK0000946840instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMeritage Pharma, Inc.us-gaap_VariableInterestEntitiesByClassificationOfEntityAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_VariableInterestEntityNotPrimaryBeneficiaryMemberus-gaap_VariableInterestEntitiesByClassificationOfEntityAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Maximum4true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0License and research agreements disclosures5false 4vphm_BusinessDevelopmentAgreementPotentialCashPaymentvphm_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse50000005.0USD$falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse50000005.0USD$falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the option for payment of cash under business development agreement.No definition available.false2Business development agreement, potential cash payment6false 4us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPaymentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse175000000175USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of potential cash payments that could result from the contingent consideration arrangement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph f -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Contingent consideration, potential cash payment7false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse4false USDtruefalse$D2013Q3_M07_CostmethodInvestmentsMember_VariableInterestEntityNotPrimaryBeneficiaryMemberhttp://www.sec.gov/CIK0000946840duration2013-07-01T00:00:002013-07-31T00:00:00falsefalseMeritage Pharma, Inc.us-gaap_VariableInterestEntitiesByClassificationOfEntityAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_VariableInterestEntityNotPrimaryBeneficiaryMemberus-gaap_VariableInterestEntitiesByClassificationOfEntityAxisexplicitMemberfalsefalseCost-method investmentus-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CostmethodInvestmentsMemberus-gaap_MajorTypesOfDebtAndEquitySecuritiesAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Cost-method investment8true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0License and research agreements disclosures9false 4us-gaap_PaymentsToAcquireOtherInvestmentsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse25000002.5USD$falsefalsefalse2truefalsefalse75000007.5USD$falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse50000005.0USD$falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow associated with other investments held by the entity for investment purposes not otherwise defined in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Payment to purchase interest in development company10false 4vphm_PercentageOfSubjectsPlannedForPhaseTwoStudyEnrollmentvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truetruefalse0.500.50falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalsenum:percentItemTypepureRepresents the percentage of subjects planned for the Phase 2 study enrollment.No definition available.false0Percentage of subjects planned for the Phase 2 study enrollment11false 4us-gaap_OtherDeferredCostAmortizationExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse11000001.1USD$falsetruefalse4falsefalsefalse00falsefalsefalse5truefalsefalse6000000.6USD$falsetruefalse6truefalsefalse22000002.2USD$falsetruefalse7truefalsefalse17000001.7USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of other deferred costs charged against earnings in the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Amortization expensefalseAcquisitions, License and Research Agreements (Details 2) (Meritage Pharma, Inc., USD $)HundredThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.viropharma.com/role/DisclosureAcquisitionsLicenseAndResearchAgreementsDetails2711